| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14712598.7.11.1763 |
| P698 | PubMed publication ID | 17961098 |
| P50 | author | Jean-Louis Vincent | Q3167023 |
| P2860 | cites work | Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon | Q24563760 |
| Pro/con clinical debate: isolation precautions for all intensive care unit patients with methicillin-resistant Staphylococcus aureus colonization are essential | Q24791088 | ||
| Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis | Q24794551 | ||
| Clinical review: the Israeli experience: conventional terrorism and critical care | Q24813211 | ||
| The cytoprotective protein C pathway | Q28274500 | ||
| The epidemiology of sepsis in the United States from 1979 through 2000 | Q29547760 | ||
| Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 | ||
| Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden | Q31003628 | ||
| Risks and benefits of activated protein C treatment for severe sepsis | Q34151715 | ||
| Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis | Q34303824 | ||
| Activated protein C versus protein C in severe sepsis | Q34303838 | ||
| Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock | Q34314380 | ||
| Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death | Q34455153 | ||
| Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial | Q34518326 | ||
| Clinical trials of immunomodulatory therapies in severe sepsis and septic shock | Q34577529 | ||
| The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database | Q34999455 | ||
| Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury | Q35629866 | ||
| Endogenous protein C activation in patients with severe sepsis | Q35760617 | ||
| Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. | Q36073243 | ||
| Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition | Q36259598 | ||
| New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). | Q36259602 | ||
| Inflammation and the activated protein C anticoagulant pathway | Q36467895 | ||
| Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey | Q36746414 | ||
| Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. | Q36746418 | ||
| Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin | Q37041393 | ||
| Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. | Q40235280 | ||
| Epidemiology of sepsis in Germany: results from a national prospective multicenter study | Q40239427 | ||
| Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. | Q40461020 | ||
| Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications | Q40617503 | ||
| Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor | Q40657744 | ||
| Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis | Q40677074 | ||
| Assessing the use of activated protein C in the treatment of severe sepsis | Q40701367 | ||
| Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line | Q40863608 | ||
| Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome | Q42905403 | ||
| Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis | Q43606634 | ||
| Low levels of protein C are associated with poor outcome in severe sepsis | Q43736384 | ||
| Microvascular blood flow is altered in patients with sepsis | Q44045816 | ||
| Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies | Q44075032 | ||
| Expression and function of the endothelial protein C receptor in human neutrophils | Q44417143 | ||
| Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial | Q44506875 | ||
| Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling | Q44876480 | ||
| Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model | Q45256622 | ||
| Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation | Q45264873 | ||
| Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany | Q47301773 | ||
| Activated protein C variants with normal cytoprotective but reduced anticoagulant activity | Q47392002 | ||
| Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. | Q47614282 | ||
| Severe protein C deficiency predicts early death in severe sepsis | Q47670659 | ||
| Effects of drotrecogin alfa (activated) in human endotoxemia | Q48021028 | ||
| Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom | Q48806120 | ||
| The epidemiology of severe sepsis in children in the United States. | Q50710556 | ||
| Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. | Q50738804 | ||
| Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. | Q51683065 | ||
| Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. | Q53238938 | ||
| INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. | Q53366008 | ||
| Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. | Q53850410 | ||
| Sepsis in European intensive care units: results of the SOAP study. | Q54471944 | ||
| Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. | Q54569673 | ||
| Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. | Q54746049 | ||
| Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans | Q56172334 | ||
| The Protein C Pathway | Q56502503 | ||
| Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis | Q57195132 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| drotrecogin alfa | Q412888 | ||
| P304 | page(s) | 1763-1777 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Drotrecogin alpha (activated): the treatment for severe sepsis? | |
| P478 | volume | 7 |
Search more.